Research programme - small molecule degraders - Bristol Myers Squibb/SyntheX Labs
Latest Information Update: 14 Nov 2022
At a glance
- Originator Bristol-Myers Squibb; SyntheX Labs
- Class Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified